| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 上海现代制药股份有限公司是一家以原料药和制剂的生产为主业的医药企业.公司产品覆盖原料药和制剂、药物新型制剂和生物药品三大领域,主导产品包括阿奇霉素、硫辛酸、头孢氨苄缓释胶囊、硝苯地平控释片和人尿制品等.公司是国内颇具优势的缓释药技术产品生产厂家,生产的头孢氨苄缓释胶囊销量占国内同类产品市场的一半份额以上,独家生产的硝苯地平控释片广泛用于治疗高血压和心绞痛,知名度较高.公司在产品种约20个,而储备品种数目也已达到20多个,具有较为丰富的储备品种资源.荣誉申报提升品牌内功,"现代"是上海市著名商标、"欣然"申报上海市著名商标的申请已被受理,4个产品已成为上海市名牌产品[现代(马来酸依那普利片)、现代(硫辛酸原料)、欣然(硝苯地平控释片)、申嘉(头孢氨苄缓释胶囊)],4个产品成为自主创新品牌[现代(马来酸依那普利片)、欣然(硝苯地平控释片)、申嘉(头孢氨苄缓释胶囊)、浦乐齐(阿奇霉素片)],5个产品成为上海市名优产品[欣然(硝苯地平控释片)、申嘉(头孢氨苄缓释胶囊)、申洛(头孢克洛缓释胶囊)、申嘉(头孢氨苄缓释胶囊)、现代(马来酸依那普利片)]。 | ||||||||||||||||||||||||
| Main Business | 医药中间体和原料药以及新型制剂类药物的研发、生产和销售 | ||||||||||||||||||||||||
| Legal Representative | 董增贺 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 魏冬松 | ||||||||||||||||||||||||
| Solicitors | 国浩律师（北京）事务所 | ||||||||||||||||||||||||
| Auditors | 天健会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 021-52372865 | ||||||||||||||||||||||||
| Fax No | 021-58480136 | ||||||||||||||||||||||||
| Website | www.shyndec.com | ||||||||||||||||||||||||
| shyndec@sinopharm.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 16/06/2004 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.543 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.100 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 9.237 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 12.977B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |